DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia - PubMed (original) (raw)
. 2010 Jan 19;17(1):13-27.
doi: 10.1016/j.ccr.2009.11.020. Epub 2010 Jan 7.
Sanne Lugthart, Yushan Li, Claudia Erpelinck-Verschueren, Xutao Deng, Paul J Christos, Elizabeth Schifano, James Booth, Wim van Putten, Lucy Skrabanek, Fabien Campagne, Madhu Mazumdar, John M Greally, Peter J M Valk, Bob Löwenberg, Ruud Delwel, Ari Melnick
Affiliations
- PMID: 20060365
- PMCID: PMC3008568
- DOI: 10.1016/j.ccr.2009.11.020
DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia
Maria E Figueroa et al. Cancer Cell. 2010.
Abstract
We hypothesized that DNA methylation distributes into specific patterns in cancer cells, which reflect critical biological differences. We therefore examined the methylation profiles of 344 patients with acute myeloid leukemia (AML). Clustering of these patients by methylation data segregated patients into 16 groups. Five of these groups defined new AML subtypes that shared no other known feature. In addition, DNA methylation profiles segregated patients with CEBPA aberrations from other subtypes of leukemia, defined four epigenetically distinct forms of AML with NPM1 mutations, and showed that established AML1-ETO, CBFb-MYH11, and PML-RARA leukemia entities are associated with specific methylation profiles. We report a 15 gene methylation classifier predictive of overall survival in an independent patient cohort (p < 0.001, adjusted for known covariates).
Copyright (c) 2010 Elsevier Inc. All rights reserved.
Figures
Figure 1. DNA Methylation Segregates AML Patients into 16 Groups
Heatmap representation of a correlation matrix in which each patient’s DNA methylation profile is correlated with that of the other patients in the data set. Patients are ordered according to the unsupervised analysis (hierarchical clustering) results, so that highly correlated patients are located next to each other. Parallel bars on the right of the heatmap have been used to indicate the principal cytogenetic and molecular findings for each patient. Cluster membership and cluster feature summaries are described on the left of the heatmap. Additional information is shown in Figure S1.
Figure 2. Distinct DNA Methylation Signatures Define each of the 16 Clusters
Heatmap representation of the aberrant DNA methylation signatures of specific clusters compared with a cohort of normal CD34+ hematopoietic cells obtained from healthy donors. Each row of the heatmap represents one probe set of the HELP array, and each column represents an AML patient (denoted by light brown bars) or a healthy donor (denoted by dark brown bars). (A) DNA methylation signatures for clusters with recurrent translocations, (B) DNA methylation signatures associated with abnormalities of CEBPA, (C) DNA methylation signatures for clusters presenting NPM1 mutations, (D) DNA methylation signatures for the five epigenetically defined clusters. The complete information for each cluster is contained in Table S3.
Figure 3. DNA Methylation Captures Clinically Significant Differences among AML Patients
(A) Left: Kaplan-Meier curves for overall survival for the favorable risk clusters 1 (inv(16)) and 4 (_CEBPA_-dm), and the novel epigenetically defined clusters. For plotting simplicity curves for clusters 3 (t[8;21]), cluster 5 and cluster 15 were not included in the plot. Figure S3 shows a Kaplan-Meier plot including all the clusters in the overall survival analysis. Right: Kaplan-Meier curves for overall survival for the favorable risk clusters 1 (inv[16]) and 4 (_CEBPA_-dm), and the NPM1 clusters. For plotting simplicity, curves for clusters 3 (t[8;21]) and NPM1 cluster 14 were not included in the plot. Figure S3 shows a Kaplan-Meier plot including all the clusters in the overall survival analysis. (B) Kaplan-Meier curves for overall survival (left) for the five novel clusters. Right: Table summarizing the multivariate Cox proportional hazards regression model, using cluster 1 (inv[16]) as the referent cluster. Additional Kaplan Meier plots are shown in Figure S3.
Figure 4. Pathway Analysis for the Epigenetically Defined Clusters
(A) Top scoring aberrantly expressed gene networks for each of the five epigenetically defined clusters. Genes overexpressed compared with normal CD34+ cells are colored in red, whereas downregulated genes appear in green. (B) Comparative analysis of the most significantly deregulated canonical pathways of the five epigenetically defined clusters as captured by an integration of the aberrant epigenetic and gene expression signatures.
Figure 5. 45 Genes Are Consistently Aberrantly Methylated in AML
(A) Heatmap representation of the common 45 gene signature consistently aberrantly methylated in AML. Each row represents a probe set from the HELP microarray and each column represents a sample. (B) Boxplots of gene expression levels in 4 representative genes from the 45 gene common epigenetic signature demonstrating downregulation of expression in the AML samples compared with normal CD34+ cells. The list of genes is shown in Table S4.
Figure 6. A DNA Methylation Classifier Predicts Clinical Outcome in AML Patients
(A) Outline describing the steps for building the DNA methylation classifier. In a first step, 200 randomly selected patients were used to identify HELP probe sets that best predicted survival. The model was then tested on a different cohort of 95 patients (test set). Once the final model was selected, its performance in predicting survival was tested in an independent validation set consisting of 49 randomly selected cases. (B) Kaplan-Meier curves for overall survival for the predicted groups in the independent validation set. Overall survival was compared between patients in an independent validation set that were predicted either alive or deceased by the DNA methylation classifier. (Cox proportional hazards p < 0.005, hazard ratio = 1.39, 95% CI = 1.10, 1.75). (C) Kaplan-Meier curves for event-free survival for the predicted groups in the independent validation set. Event-free survival was compared between patients in an independent validation set that were predicted either alive or deceased by the DNA methylation classifier (Cox proportional hazards p < 0.0002, hazard ratio: 1.53, 95% CI = 1.21, 1.93). (D) Kaplan-Meier curves for overall survival for the predicted groups in the combined test and independent validation sets. Overall survival was compared between patients in the combined test and independent validation sets that were predicted either alive or deceased by the DNA methylation classifier. (Cox Proportional hazards p < 0.000003, hazard ratio: 1.34, 95% CI = 1.18, 1.51). (E) Multivariate Cox proportional hazards regression model for the DNA methylation predictor, age, cytogenetic risk, NPM1 mutation, _FLT3_-ITD and CEBPA mutations. For additional information please see Tables S5, S6, S7, and S8, as well as supplementary R scripts.
Comment in
- HELP for AML: methylation profiling opens new avenues.
Bullinger L, Armstrong SA. Bullinger L, et al. Cancer Cell. 2010 Jan 19;17(1):1-3. doi: 10.1016/j.ccr.2009.12.033. Cancer Cell. 2010. PMID: 20129241 Review.
Similar articles
- CBFB-MYH11 hypomethylation signature and PBX3 differential methylation revealed by targeted bisulfite sequencing in patients with acute myeloid leukemia.
Hájková H, Fritz MH, Haškovec C, Schwarz J, Šálek C, Marková J, Krejčík Z, Dostálová Merkerová M, Kostečka A, Vostrý M, Fuchs O, Michalová K, Cetkovský P, Beneš V. Hájková H, et al. J Hematol Oncol. 2014 Sep 30;7:66. doi: 10.1186/s13045-014-0066-4. J Hematol Oncol. 2014. PMID: 25266220 Free PMC article. - DNA methylation profiles and their relationship with cytogenetic status in adult acute myeloid leukemia.
Alvarez S, Suela J, Valencia A, Fernández A, Wunderlich M, Agirre X, Prósper F, Martín-Subero JI, Maiques A, Acquadro F, Rodriguez Perales S, Calasanz MJ, Roman-Gómez J, Siebert R, Mulloy JC, Cervera J, Sanz MA, Esteller M, Cigudosa JC. Alvarez S, et al. PLoS One. 2010 Aug 16;5(8):e12197. doi: 10.1371/journal.pone.0012197. PLoS One. 2010. PMID: 20808941 Free PMC article. - Reduced protocadherin17 expression in leukemia stem cells: the clinical and biological effect in acute myeloid leukemia.
Xu ZJ, Ma JC, Zhou JD, Wen XM, Yao DM, Zhang W, Ji RB, Wu DH, Tang LJ, Deng ZQ, Qian J, Lin J. Xu ZJ, et al. J Transl Med. 2019 Mar 29;17(1):102. doi: 10.1186/s12967-019-1851-1. J Transl Med. 2019. PMID: 30922328 Free PMC article. - Clinical implications of genome-wide DNA methylation studies in acute myeloid leukemia.
Li Y, Xu Q, Lv N, Wang L, Zhao H, Wang X, Guo J, Chen C, Li Y, Yu L. Li Y, et al. J Hematol Oncol. 2017 Feb 2;10(1):41. doi: 10.1186/s13045-017-0409-z. J Hematol Oncol. 2017. PMID: 28153026 Free PMC article. Review. - Molecular biomarkers in acute myeloid leukemia.
Prada-Arismendy J, Arroyave JC, Röthlisberger S. Prada-Arismendy J, et al. Blood Rev. 2017 Jan;31(1):63-76. doi: 10.1016/j.blre.2016.08.005. Epub 2016 Sep 2. Blood Rev. 2017. PMID: 27639498 Review.
Cited by
- TCA metabolism regulates DNA hypermethylation in LPS and _Mycobacterium tuberculosis_-induced immune tolerance.
Abhimanyu, Longlax SC, Nishiguchi T, Ladki M, Sheikh D, Martinez AL, Mace EM, Grimm SL, Caldwell T, Portillo Varela A, Sekhar RV, Mandalakas AM, Mlotshwa M, Ginidza S, Cirillo JD, Wallis RS, Netea MG, van Crevel R, Coarfa C, DiNardo AR. Abhimanyu, et al. Proc Natl Acad Sci U S A. 2024 Oct 8;121(41):e2404841121. doi: 10.1073/pnas.2404841121. Epub 2024 Sep 30. Proc Natl Acad Sci U S A. 2024. PMID: 39348545 - Identification of leukemia stem cell subsets with distinct transcriptional, epigenetic and functional properties.
Boutzen H, Murison A, Oriecuia A, Bansal S, Arlidge C, Wang JCY, Lupien M, Kaufmann KB, Dick JE. Boutzen H, et al. Leukemia. 2024 Oct;38(10):2090-2101. doi: 10.1038/s41375-024-02358-9. Epub 2024 Aug 21. Leukemia. 2024. PMID: 39169113 Free PMC article. - Identification of Novel DNA Methylation Prognostic Biomarkers for AML With Normal Cytogenetics.
Cardoso C, Pestana D, Gokuladhas S, Marreiros AD, O'Sullivan JM, Binnie A, TFernandes M, Castelo-Branco P. Cardoso C, et al. JCO Clin Cancer Inform. 2024 Jul;8:e2300265. doi: 10.1200/CCI.23.00265. JCO Clin Cancer Inform. 2024. PMID: 39052947 Free PMC article. - Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias.
Kwon MC, Thuring JW, Querolle O, Dai X, Verhulst T, Pande V, Marien A, Goffin D, Wenge DV, Yue H, Cutler JA, Jin C, Perner F, Hogeling SM, Shaffer PL, Jacobs F, Vinken P, Cai W, Keersmaekers V, Eyassu F, Bhogal B, Verstraeten K, El Ashkar S, Perry JA, Jayaguru P, Barreyro L, Kuchnio A, Darville N, Krosky D, Urbanietz G, Verbist B, Edwards JP, Cowley GS, Kirkpatrick R, Steele R, Ferrante L, Guttke C, Daskalakis N, Pietsch EC, Wilson DM, Attar R, Elsayed Y, Fischer ES, Schuringa JJ, Armstrong SA, Packman K, Philippar U. Kwon MC, et al. Blood. 2024 Sep 12;144(11):1206-1220. doi: 10.1182/blood.2023022480. Blood. 2024. PMID: 38905635 Free PMC article. - Effect of DNMT3A R882H Hot Spot Mutations on DDX43 Promoter Methylation in Acute Myeloid Leukemia.
Tabatabaei T, Rezvany MR, Ghasemi B, Vafaei F, Zadeh MK, Zaker F, Salmaninejad A. Tabatabaei T, et al. Biomed Res Int. 2024 May 21;2024:9625043. doi: 10.1155/2024/9625043. eCollection 2024. Biomed Res Int. 2024. PMID: 38807916 Free PMC article.
References
- Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R, Patil SR, Davey FR, Berg DT, Schiffer CA, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res. 1998;58:4173–4179. - PubMed
- Cameron EE, Baylin SB, Herman JG. p15(INK4B) CpG island methylation in primary acute leukemia is heterogeneous and suggests density as a critical factor for transcriptional silencing. Blood. 1999;94:2445–2451. - PubMed
- Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia. 2003;17:1813–1819. - PubMed
- Chessel D, Dufour AB, Thioulouse J. The ade4 package - I: One-table methods. R News. 2004;4:5–10.
Publication types
MeSH terms
Substances
Grants and funding
- UL1 RR024996-01/RR/NCRR NIH HHS/United States
- CA118316/CA/NCI NIH HHS/United States
- UL1-RR024996/RR/NCRR NIH HHS/United States
- R01 HD044078/HD/NICHD NIH HHS/United States
- R01 CA104348/CA/NCI NIH HHS/United States
- UL1 RR024996/RR/NCRR NIH HHS/United States
- R01 CA118316/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical